In vitro activities of doripenem and other carbapenems against clinically important bacteria isolated in intensive care units: Nationwide data from the SMART Programme

S. S. Jean, P. R. Hsueh, W. S. Lee, H. T. Chang, M. Y. Chou, I. S. Chen, J. H. Wang, C. F. Lin, J. M. Shyr, W. C. Ko, J. J. Wu, Y. C. Liu, W. K. Huang, L. J. Teng, C. Y. Liu

研究成果: 雜誌貢獻文章

15 引文 (Scopus)

摘要

This nationwide surveillance of clinically important bacteria from the intensive care units (ICUs) of major teaching hospitals throughout Taiwan investigated the susceptibilities to doripenem and other comparator carbapenems from September through November 2005. Minimum inhibitory concentrations (MICs) were determined for 1,311 clinical isolates using the broth microdilution method according to Clinical and Laboratory Standards Institute (CLSI) 2005 guidelines. Doripenem showed similar (within four-fold difference of MICs) in vitro activity to meropenem for Enterobacteriaceae and probably comparable activity to meropenem against important nosocomial non-fermentative Gram-negative bacilli (NFGNBs), including Pseudomonas aeruginosa, Acinetobacter baumannii and Burkholderia cepacia. Among the four carbapenems analysed, doripenem and meropenem exhibited better in vitro activity than imipenem or ertapenem against extended-spectrum β-lactamase (ESBL)-producing Klebsiella pneumoniae and Escherichia coli isolates. However, the meropenem MIC 90 against ESBL-producing K. pneumoniae isolates was 2 μg/ml. Besides, doripenem with the MIC90 of 0.5 μg/ml to Streptococcus pneumoniae possibly suggested its potential therapeutic effect regarding community-acquired pneumonia. Because of the heavy resistance burden in Taiwan, closely monitoring the evolutionary trend of carbapenem susceptibilities against clinically important pathogens is crucial in the future.

原文英語
頁(從 - 到)471-475
頁數5
期刊European Journal of Clinical Microbiology and Infectious Diseases
29
發行號4
DOIs
出版狀態已發佈 - 四月 2010
對外發佈Yes

指紋

meropenem
doripenem
Carbapenems
Intensive Care Units
Microbial Sensitivity Tests
Bacteria
Klebsiella pneumoniae
Taiwan
Burkholderia cepacia
Acinetobacter baumannii
Imipenem
Therapeutic Uses
Enterobacteriaceae
Streptococcus pneumoniae
Teaching Hospitals
Pseudomonas aeruginosa
Bacillus
Pneumonia
Guidelines
Escherichia coli

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

引用此文

In vitro activities of doripenem and other carbapenems against clinically important bacteria isolated in intensive care units : Nationwide data from the SMART Programme. / Jean, S. S.; Hsueh, P. R.; Lee, W. S.; Chang, H. T.; Chou, M. Y.; Chen, I. S.; Wang, J. H.; Lin, C. F.; Shyr, J. M.; Ko, W. C.; Wu, J. J.; Liu, Y. C.; Huang, W. K.; Teng, L. J.; Liu, C. Y.

於: European Journal of Clinical Microbiology and Infectious Diseases, 卷 29, 編號 4, 04.2010, p. 471-475.

研究成果: 雜誌貢獻文章

Jean, S. S. ; Hsueh, P. R. ; Lee, W. S. ; Chang, H. T. ; Chou, M. Y. ; Chen, I. S. ; Wang, J. H. ; Lin, C. F. ; Shyr, J. M. ; Ko, W. C. ; Wu, J. J. ; Liu, Y. C. ; Huang, W. K. ; Teng, L. J. ; Liu, C. Y. / In vitro activities of doripenem and other carbapenems against clinically important bacteria isolated in intensive care units : Nationwide data from the SMART Programme. 於: European Journal of Clinical Microbiology and Infectious Diseases. 2010 ; 卷 29, 編號 4. 頁 471-475.
@article{c8a49ec70f104e61a157950ed40a0f8a,
title = "In vitro activities of doripenem and other carbapenems against clinically important bacteria isolated in intensive care units: Nationwide data from the SMART Programme",
abstract = "This nationwide surveillance of clinically important bacteria from the intensive care units (ICUs) of major teaching hospitals throughout Taiwan investigated the susceptibilities to doripenem and other comparator carbapenems from September through November 2005. Minimum inhibitory concentrations (MICs) were determined for 1,311 clinical isolates using the broth microdilution method according to Clinical and Laboratory Standards Institute (CLSI) 2005 guidelines. Doripenem showed similar (within four-fold difference of MICs) in vitro activity to meropenem for Enterobacteriaceae and probably comparable activity to meropenem against important nosocomial non-fermentative Gram-negative bacilli (NFGNBs), including Pseudomonas aeruginosa, Acinetobacter baumannii and Burkholderia cepacia. Among the four carbapenems analysed, doripenem and meropenem exhibited better in vitro activity than imipenem or ertapenem against extended-spectrum β-lactamase (ESBL)-producing Klebsiella pneumoniae and Escherichia coli isolates. However, the meropenem MIC 90 against ESBL-producing K. pneumoniae isolates was 2 μg/ml. Besides, doripenem with the MIC90 of 0.5 μg/ml to Streptococcus pneumoniae possibly suggested its potential therapeutic effect regarding community-acquired pneumonia. Because of the heavy resistance burden in Taiwan, closely monitoring the evolutionary trend of carbapenem susceptibilities against clinically important pathogens is crucial in the future.",
author = "Jean, {S. S.} and Hsueh, {P. R.} and Lee, {W. S.} and Chang, {H. T.} and Chou, {M. Y.} and Chen, {I. S.} and Wang, {J. H.} and Lin, {C. F.} and Shyr, {J. M.} and Ko, {W. C.} and Wu, {J. J.} and Liu, {Y. C.} and Huang, {W. K.} and Teng, {L. J.} and Liu, {C. Y.}",
year = "2010",
month = "4",
doi = "10.1007/s10096-009-0866-6",
language = "English",
volume = "29",
pages = "471--475",
journal = "European Journal of Clinical Microbiology and Infectious Diseases",
issn = "0934-9723",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - In vitro activities of doripenem and other carbapenems against clinically important bacteria isolated in intensive care units

T2 - Nationwide data from the SMART Programme

AU - Jean, S. S.

AU - Hsueh, P. R.

AU - Lee, W. S.

AU - Chang, H. T.

AU - Chou, M. Y.

AU - Chen, I. S.

AU - Wang, J. H.

AU - Lin, C. F.

AU - Shyr, J. M.

AU - Ko, W. C.

AU - Wu, J. J.

AU - Liu, Y. C.

AU - Huang, W. K.

AU - Teng, L. J.

AU - Liu, C. Y.

PY - 2010/4

Y1 - 2010/4

N2 - This nationwide surveillance of clinically important bacteria from the intensive care units (ICUs) of major teaching hospitals throughout Taiwan investigated the susceptibilities to doripenem and other comparator carbapenems from September through November 2005. Minimum inhibitory concentrations (MICs) were determined for 1,311 clinical isolates using the broth microdilution method according to Clinical and Laboratory Standards Institute (CLSI) 2005 guidelines. Doripenem showed similar (within four-fold difference of MICs) in vitro activity to meropenem for Enterobacteriaceae and probably comparable activity to meropenem against important nosocomial non-fermentative Gram-negative bacilli (NFGNBs), including Pseudomonas aeruginosa, Acinetobacter baumannii and Burkholderia cepacia. Among the four carbapenems analysed, doripenem and meropenem exhibited better in vitro activity than imipenem or ertapenem against extended-spectrum β-lactamase (ESBL)-producing Klebsiella pneumoniae and Escherichia coli isolates. However, the meropenem MIC 90 against ESBL-producing K. pneumoniae isolates was 2 μg/ml. Besides, doripenem with the MIC90 of 0.5 μg/ml to Streptococcus pneumoniae possibly suggested its potential therapeutic effect regarding community-acquired pneumonia. Because of the heavy resistance burden in Taiwan, closely monitoring the evolutionary trend of carbapenem susceptibilities against clinically important pathogens is crucial in the future.

AB - This nationwide surveillance of clinically important bacteria from the intensive care units (ICUs) of major teaching hospitals throughout Taiwan investigated the susceptibilities to doripenem and other comparator carbapenems from September through November 2005. Minimum inhibitory concentrations (MICs) were determined for 1,311 clinical isolates using the broth microdilution method according to Clinical and Laboratory Standards Institute (CLSI) 2005 guidelines. Doripenem showed similar (within four-fold difference of MICs) in vitro activity to meropenem for Enterobacteriaceae and probably comparable activity to meropenem against important nosocomial non-fermentative Gram-negative bacilli (NFGNBs), including Pseudomonas aeruginosa, Acinetobacter baumannii and Burkholderia cepacia. Among the four carbapenems analysed, doripenem and meropenem exhibited better in vitro activity than imipenem or ertapenem against extended-spectrum β-lactamase (ESBL)-producing Klebsiella pneumoniae and Escherichia coli isolates. However, the meropenem MIC 90 against ESBL-producing K. pneumoniae isolates was 2 μg/ml. Besides, doripenem with the MIC90 of 0.5 μg/ml to Streptococcus pneumoniae possibly suggested its potential therapeutic effect regarding community-acquired pneumonia. Because of the heavy resistance burden in Taiwan, closely monitoring the evolutionary trend of carbapenem susceptibilities against clinically important pathogens is crucial in the future.

UR - http://www.scopus.com/inward/record.url?scp=77952097095&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952097095&partnerID=8YFLogxK

U2 - 10.1007/s10096-009-0866-6

DO - 10.1007/s10096-009-0866-6

M3 - Article

C2 - 20108018

AN - SCOPUS:77952097095

VL - 29

SP - 471

EP - 475

JO - European Journal of Clinical Microbiology and Infectious Diseases

JF - European Journal of Clinical Microbiology and Infectious Diseases

SN - 0934-9723

IS - 4

ER -